Can innovative contracts keep pace with curative therapies? Hemgenix’s 10-year deal in Europe might be the future. This episode unpacks how and why it worked.

Value alignment is especially difficult in rare diseases. In this Fireside Chat, we explore why and how manufacturers can create space for productive negotiation.

Payers and manufacturers often see evidence differently. This episode explores why value mismatches happen and how pharma can bridge the gap.

Can pricing adjust to differences in treatment response? Denmark shows how tiered pricing made SMA access more equitable. Learn how payers evaluate subpopulation efficacy.

Which drug goes first in a combination launch can make or break your pricing strategy. In this episode, we explore the ripple effects of sequencing decisions.

How should we price oncology therapies that deliver only incremental benefit in combinations? This Fireside Chat unpacks how payers evaluate value in complex cancer regimens.

Spanish payer Jaime Espín joins Omar Ali to discuss regulatory reform, transparency in pricing, and the evolving use of outcome-based payment models in Spain’s healthcare system.

Dutch HTA expert Hans Severens speaks with Omar Ali about value-based pricing, disease severity as a modifier, and the challenges of system sustainability in the Netherlands.

Italian AIFA member Fabrizio Gianfrate joins Omar Ali to discuss rare disease pricing, payment-over-time challenges, and the realities of reimbursement in the Italian healthcare system.

German payer Detlev Parow joins Verpora’s Omar Ali to discuss obesity, indication-based pricing, and risk-sharing models for gene therapies in one of Europe’s most complex healthcare systems.

Former CEPS member Jean-Claude Castanier joins Verpora’s Omar Ali to discuss France’s approach to multi-indication pricing, transparency, and long-term healthcare system sustainability.

Patient feedback changed the conversation on access for Botox in migraine care — watch how real-world insights reshaped value and future possibilities for innovative contracting.

Through the eyes of Omar Ali - a former NICE insider; a 30,000-foot full-throttle take on the collapse of NHS England's structure – and the ripple effects across commissioning, VPAG, NICE, ICBs and pharma's next move.

Performance-based agreements in China seemed impossible — until one deal showed what was possible. Watch how it built trust, access, and a path forward for markets worldwide.

Unlike cheap oral drugs, early PCSK9s were high-cost injections — and a tough sell. But one manufacturer used a VBA to secure trust and gain early access.

Watch the latest Verpora webinar on IRA Medicare drug price negotiations. Explore how CMS’s approach is shifting from IPAY 2026 to 2027, and what manufacturers should prepare for in IPAY 2028 and beyond. Access available by request.

Why do innovative contracts fail? Omar Ali and Adam Buckler explore real-world VBAs that didn’t launch—and what those failures teach us about doing it right.

How do you revive innovation in antibiotics? Explore the bold subscription models rewarding pharma for availability—not volume.

Oncology. Multiple indications. One bold move changed the pricing playbook. Watch how Roche did it.

Physician buy-in can make or break an innovative contract. In this episode, we explore real-world strategies to engage prescribers, overcome resistance, and drive adoption.